Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

About this update from Syndax Pharmaceuticals, Inc.

[{"type":"image","alt":"Syndax Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Syndax Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/5775244779f64273f7aa7061ff889f13"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_ptZtiFyc.aKqHQuNuhUmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5775244779f64273f7aa7061ff889f13","width":300,"height":80}},"lazy":false},{"type":"text","content":"NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026.","length":320,"tagName":"p"},{"type":"text","content":"In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026.","length":163,"tagName":"p"},{"type":"text","content":"The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:","length":235,"tagName":"p"},{"type":"text","content":"Conference ID: Syndax4Q25Domestic Dial-in Number: 800-590-8290International Dial-in Number: 240-690-8800Live webcast: https://sndx-4q25.open-exchange.net/","length":157,"tagName":"p"},{"type":"text","content":"For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.","length":268,"tagName":"p"},{"type":"text","content":"About Syndax","length":12,"tagName":"p"},{"type":"text","content":"Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1...

More updates from Syndax Pharmaceuticals, Inc.